|  |
| --- |
| **Supplemental Table 1** |
| **Milestones for Year 1 of Grant** | **Completion Date** |
| 1. NHLBI and NIAID Approved interim data analysis plan to assess adequacy of sample size
 | Approved 10/27/14 |
| 1. Protocol team is informed by DAIDS Regulatory Affairs Branch that it is safe to proceed under IND
 | Received 1/13/15  |
| 1. IRB-approved REPRIEVE DSMP; DSMB/IRB-approved final protocol
 | DSMB approved 10/14/14IRB approved 10/29/14 |
| 1. Final REPRIEVE Manual of Operations (approved by NHLBI and NIAID)
 | Finalized 12/24/14 |
| 1. Written plans to address:
 |
| 1. Site specific monitoring plan
 | Finalized 03/03/15 |
| 1. Study Monitoring Plan (SMP)
 | Finalized 03/19/15 |
| data quality assurance (contained in SMP)  | Finalized 03/19/15 |
| recruitment/retention (Contained in SMP) | Finalized 03/19/15 |
| 1. Site Performance Plan
 | Finalized 03/19/15 |
| 1. Confirmation that DAIDS and KOWA Pharmaceuticals have executed an NHLBI approved agreement for study drug and placebo
 | Executed 10/30/14 |
| 1. Finalized electronic case report forms (eCRFs) (approved by NHLBI and NIAID)
 | Finalized 12/24/14 |
| 1. List of at least 100 participating sites
 | Completed 01/08/2015 |
| 1. IRB approvals, signed subcontracts, and site staff training completed with study open to accrual at a minimum of 15 sites
 | Completed 04/27/2015 |
| 1. Development of Trial Website
 | Finalized 03/19/15 |
| 1. Active drug and placebo obtained and ready for shipment to sites (By April 30th 2015)
 | Received by DAIDS central pharmacy 1/7/15 |
| 1. First patient in (by April 30th 2015)
 | Accomplished 03/29/2015 |
| **Milestones for Year 2 of Grant** |  |
| 1. 85 sites activated
 | Completed 05/02/16 |